GLP-1 Agonists and Exercise Capacity

Peptides and Athletic Performance

21.4% improvement in 6-minute walk distance with semaglutide in HFpEF

GLP-1 receptor agonists improve exercise capacity in heart failure patients while raising legitimate concerns about lean mass loss in active populations.

Borlaug et al., JACC, 2025

Borlaug et al., JACC, 2025

View as image

GLP-1 receptor agonists like semaglutide and tirzepatide produce weight loss of 15-22% in clinical trials, but the composition of that weight loss matters for exercise capacity. Between 15% and 40% of the weight lost on GLP-1 therapy comes from lean body mass rather than fat, a ratio that raises questions about physical performance, strength, and long-term metabolic health. At the same time, the STEP-HFpEF trials demonstrated that semaglutide improved exercise function in obese heart failure patients, a population where excess fat directly impairs cardiovascular performance. The relationship between GLP-1 drugs and exercise capacity is not a simple story of gain or loss. It depends on who is being treated, what kind of exercise is being measured, and whether concurrent exercise training accompanies the pharmacological intervention. For the broader context of peptides in athletic performance, see the pillar article on EPO: the peptide that defined endurance doping.

How GLP-1 Drugs Improve Exercise Capacity in Heart Failure

The strongest evidence for GLP-1 agonists improving exercise capacity comes from the STEP-HFpEF program, which tested semaglutide 2.4 mg weekly in obese patients with heart failure with preserved ejection fraction (HFpEF). This condition directly links excess body fat to impaired cardiac function: the extra weight increases blood volume, raises filling pressures, and limits the heart's ability to increase output during exertion.

Kosiborod et al. (2023) published the landmark STEP-HFpEF trial showing semaglutide improved symptoms, physical limitations, and exercise function in obese HFpEF patients over 52 weeks compared to placebo. The Kansas City Cardiomyopathy Questionnaire clinical summary score improved by 7.8 points more with semaglutide than placebo, and body weight decreased by 10.7% versus 3.1%. Exercise capacity, measured by the 6-minute walk test, showed meaningful improvement.^[1]

Borlaug et al. (2025) conducted a dedicated analysis of exercise function from the STEP-HFpEF program. Semaglutide increased 6-minute walk distance by 21.4 meters compared to placebo. The improvements occurred across all baseline NYHA functional classes and were accompanied by improvements in peak oxygen consumption (VO2) and ventilatory efficiency. These are not trivial gains for a population where walking 6 minutes is a meaningful clinical test of function.^[2]

Pandey et al. (2025) showed that semaglutide's benefits in STEP-HFpEF extended across all frailty levels, and the drug actually improved frailty itself. Frailer patients, who have the least physiological reserve and the most to lose from lean mass depletion, showed consistent benefit rather than disproportionate harm. This finding partially addresses the concern that weight loss in frail older adults inevitably worsens physical function.^[3]

The mechanism behind exercise improvement in HFpEF is primarily hemodynamic: reducing body mass decreases the workload on the heart during exertion, lowers filling pressures, and improves the ratio of cardiac output to metabolic demand. Fat loss also reduces systemic inflammation (adipose tissue is an active endocrine organ producing inflammatory cytokines like IL-6 and TNF-alpha) and improves endothelial function, both of which contribute to better exercise tolerance. In this population, the benefits of losing excess fat far outweigh the costs of losing some lean mass.

The exercise improvements in STEP-HFpEF are particularly striking because they occurred without any mandatory exercise program. Patients improved their walking capacity and cardiovascular function purely through the metabolic and hemodynamic benefits of weight loss. This raises an important question: if semaglutide alone improved 6-minute walk distance by 21 meters, what could semaglutide combined with structured cardiac rehabilitation achieve? No trial has yet tested this combination in HFpEF, but the theoretical case for synergy is strong. Exercise training independently improves endothelial function, skeletal muscle oxidative capacity, and autonomic tone, all of which complement the hemodynamic unloading that weight loss provides.

The Lean Mass Problem

Outside the HFpEF context, the lean mass question becomes more pressing. For active individuals, athletes, or older adults at risk for sarcopenia, the composition of weight loss matters as much as the magnitude.

Haner et al. (2026) reviewed the clinical implications of lean mass loss during GLP-1/GIP therapy. Across published trials, 15-45% of total weight lost on these drugs is lean body mass. The proportion varies with patient characteristics: older, more sedentary patients lose a higher proportion of lean mass, while younger patients with more initial muscle mass tend to lose proportionally more fat. The review raised particular concern about elderly patients, where lean mass loss can accelerate the progression toward sarcopenia, falls, fractures, and disability.^[4]

De Girolamo et al. (2026) offered a more nuanced perspective in their review of muscle health during incretin-based therapies. While acknowledging the lean mass reduction, they found that muscle function (measured by grip strength, gait speed, and functional tests) is generally preserved or improved during GLP-1 therapy, suggesting the lean mass lost may not all be functional contractile tissue. Some of the "lean mass" measured by DXA and bioimpedance includes water, connective tissue, and organ mass rather than pure skeletal muscle. The review concluded that muscle quality may actually improve as intramuscular fat decreases, even as total lean mass on the scale goes down.^[5]

Alissou et al. (2026) provided direct clinical evidence for this distinction in the SEMALEAN study. Patients on semaglutide 2.4 mg for 12 months lost significant fat mass and lean mass on DXA scans, but handgrip strength, a validated measure of functional muscle capacity, remained intact throughout the treatment period. This dissociation between mass loss and strength preservation suggests the clinical significance of lean mass reduction may be less alarming than the numbers alone imply.^[6]

Bredum et al. (2026) tested this distinction in obese Gottingen minipigs, finding that semaglutide-treated animals lost weight with better preservation of fat-free mass and resting energy expenditure compared to pair-fed animals receiving equivalent calorie restriction without semaglutide. This suggests GLP-1 agonists produce qualitatively different weight loss than simple caloric restriction, with relatively greater fat targeting. The mechanism may involve GLP-1 receptor-mediated effects on adipose tissue lipolysis, muscle protein turnover, or metabolic rate regulation that go beyond the simple caloric deficit the drugs create through appetite suppression. If confirmed in humans, this finding would support the argument that GLP-1-mediated weight loss is metabolically distinct from, and potentially superior to, equivalent dietary restriction.^[7]

Exercise as the Missing Variable

The most important modifier of body composition during GLP-1 therapy is concurrent exercise, particularly resistance training. Most clinical trials of semaglutide and tirzepatide did not require or standardize exercise participation, meaning the lean mass loss observed in trials reflects a largely sedentary treatment population. This is a critical methodological gap: the "15-40% lean mass loss" figure comes from studies where most participants were not exercising regularly, and extrapolating these ratios to people who engage in regular resistance training would be misleading.

The evidence for exercise as a lean mass protector during caloric deficit is decades old and robust. Resistance training stimulates muscle protein synthesis through mTOR signaling and provides a mechanical stimulus that opposes muscle atrophy pathways (including the ubiquitin-proteasome and autophagy-lysosome systems). When combined with adequate protein intake (1.2-1.6 g/kg/day), resistance training can preserve or even increase lean mass during substantial weight loss. The question is whether GLP-1 therapy's appetite suppression makes it practically difficult for patients to consume enough protein to support muscle maintenance, and whether the drugs' effects on gastric emptying and food preferences alter the quality of dietary protein intake.

Jensen et al. (2026) directly evaluated physical fitness outcomes when exercise was combined with GLP-1 receptor agonist treatment after diet-induced weight loss. The study found that combining structured exercise with GLP-1 therapy preserved physical fitness more effectively than either intervention alone. Exercise maintained cardiorespiratory fitness and muscular function while GLP-1 treatment maintained weight loss, a complementary pairing that addresses both body composition and performance simultaneously.^[8]

Holt et al. (2026) revealed an unexpected physiological interaction between exercise and GLP-1. After initial weight loss, one year of structured exercise increased natural postprandial GLP-1 secretion by 37% compared to both GLP-1 drug treatment and usual activity controls. This means exercise does not just complement GLP-1 pharmacotherapy through independent pathways; it actually enhances the body's own incretin response, potentially allowing drug dose reduction or cessation while maintaining metabolic benefits.^[9]

For the broader implications of GLP-1-induced muscle loss in older adults, see GLP-1 weight loss and sarcopenia. For how body composition changes on these drugs, see does semaglutide change your body composition?.

Pharmacological Strategies to Preserve Lean Mass

Recognizing that lean mass loss limits the long-term value of GLP-1 therapy, several pharmaceutical approaches aim to selectively preserve muscle during pharmacological weight loss.

Heymsfield et al. (2026) reported results from a phase 2 trial combining bimagrumab (a monoclonal antibody that blocks the activin type II receptor, preventing myostatin-mediated muscle atrophy) with semaglutide. The combination achieved 17.8 kg of weight loss over 48 weeks, comparable to semaglutide alone, but with substantially better lean mass preservation. Bimagrumab directly opposes the molecular signals that drive muscle protein breakdown during caloric deficit, filling the gap that GLP-1 therapy creates.^[10]

Hierholzer et al. (2026) surveyed the entire pipeline of agents being developed to mitigate lean mass loss from GLP-1/GIP therapy. The review identified SARMs (selective androgen receptor modulators), myostatin inhibitors, activin receptor antibodies, and siRNA therapies targeting muscle atrophy pathways as the most advanced candidates. Several are in phase 2 trials, driven by recognition that the next generation of obesity pharmacotherapy will need to address body composition quality, not just total weight reduction. The review noted that 15-40% lean mass loss with current GLP-1/GIP monotherapy represents a clinically meaningful limitation that the market is actively trying to solve. The economics are substantial: GLP-1 drugs are projected to generate over $100 billion in annual revenue by 2030, and any add-on therapy that preserves muscle during this treatment will capture a significant share of that market.^[11]

What This Means for Different Populations

The exercise capacity question has different answers depending on who is asking. For obese patients with heart failure or severe metabolic disease, the cardiovascular and functional improvements from GLP-1-mediated weight loss are substantial and well-documented. The lean mass loss in this context is a manageable trade-off, especially when paired with even modest physical activity.

For competitive or recreational athletes considering GLP-1 drugs for body composition, the calculus is different. Lean mass loss at rates of 15-40% of total weight lost can impair power output, strength, and sport-specific performance. The appetite suppression from these drugs can make it difficult to consume the protein and total calories needed to support training adaptation. And the gastrointestinal side effects (nausea, delayed gastric emptying) can directly impair training tolerance and workout quality.

For older adults, the stakes are highest. Age-related sarcopenia already erodes muscle mass at 3-8% per decade after age 30, and adding pharmacological lean mass loss on top of this biological trajectory can push individuals below the functional thresholds that maintain independence. In this population, GLP-1 therapy without concurrent resistance training and adequate protein intake carries the most risk relative to benefit. The clinical priority should be ensuring that weight loss improves function and independence rather than accelerating the decline toward disability that excess body fat was already driving.

For the sibling article on exercise-mimicking peptides, see MOTS-c: the mitochondrial peptide with exercise-mimetic properties. For the other sibling article, see AICAR and endurance enhancement.

The Bottom Line

GLP-1 agonists have a dual relationship with exercise capacity. In obese heart failure patients, semaglutide improved 6-minute walk distance, peak VO2, and functional class by reducing the hemodynamic burden of excess fat. In healthier populations, the 15-40% lean mass loss that accompanies GLP-1-induced weight loss raises legitimate concerns about strength, physical performance, and sarcopenia risk, though emerging data suggests muscle function may be preserved even as mass declines. Structured exercise, particularly resistance training, is the most effective modifier: it preserves both cardiorespiratory fitness and lean mass during pharmacological weight loss, and it enhances the body's own GLP-1 secretion. Pipeline therapies combining GLP-1 agonists with muscle-sparing agents like bimagrumab represent the likely next generation of obesity treatment.

Frequently Asked Questions

Does semaglutide improve exercise capacity?

Yes, in specific populations. The STEP-HFpEF trials showed semaglutide improved 6-minute walk distance by 21.4 meters in obese patients with heart failure with preserved ejection fraction (Borlaug et al., 2025). The improvement comes primarily from reducing the hemodynamic burden of excess fat on the heart. In healthy active individuals, the picture is more complex because lean mass loss may partially offset the cardiovascular benefits of fat reduction.

How much muscle do you lose on GLP-1 drugs?

Published data shows 15-45% of total weight lost on GLP-1 and GLP-1/GIP drugs is lean body mass (Haner et al., 2026). The proportion varies by age, activity level, and baseline body composition. Older, sedentary patients lose proportionally more lean mass. The SEMALEAN study (Alissou et al., 2026) found that despite measurable lean mass loss on DXA scans, handgrip strength remained intact at 12 months.

Can exercise prevent muscle loss on semaglutide?

Structured exercise, especially resistance training, is the most effective strategy for preserving lean mass during GLP-1 therapy. Jensen et al. (2026) found that combining exercise with GLP-1 treatment preserved physical fitness better than either intervention alone. Exercise also increased natural GLP-1 secretion by 37% after one year (Holt et al., 2026), meaning it complements the drug through both independent and shared mechanisms.

Is GLP-1 weight loss different from dieting?

Evidence suggests yes. In an obese minipig model, semaglutide preserved fat-free mass and resting energy expenditure better than equivalent calorie restriction alone (Bredum et al., 2026). GLP-1 agonists appear to produce qualitatively different weight loss than simple caloric restriction, with relatively greater fat targeting, though lean mass loss still occurs and is clinically relevant.

What drugs prevent muscle loss with GLP-1 therapy?

Bimagrumab, a myostatin pathway inhibitor, combined with semaglutide achieved 17.8 kg weight loss while preserving lean mass in a phase 2 trial (Heymsfield et al., 2026). SARMs, other myostatin inhibitors, activin receptor antibodies, and siRNA therapies are also in development (Hierholzer et al., 2026). None are approved for this indication yet. Resistance exercise remains the current standard approach.

Does semaglutide help frail patients exercise more?

In the STEP-HFpEF program, semaglutide improved frailty itself across all baseline frailty levels (Pandey et al., 2025). Frailer patients showed consistent exercise and symptom improvements rather than disproportionate harm from weight loss. This suggests that in obese heart failure patients, the functional benefits of fat reduction outweigh the risks of modest lean mass loss, even in the most physically compromised individuals.